News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,298 Results
Type
Article (39616)
Company Profile (247)
Press Release (657435)
Multimedia
Podcasts (47)
Webinars (12)
Section
Business (204125)
Career Advice (2007)
Deals (35413)
Drug Delivery (95)
Drug Development (81030)
Employer Resources (172)
FDA (16166)
Job Trends (14850)
News (345109)
Policy (32520)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2553)
Accelerated approval (5)
Adcomms (20)
Allergies (82)
Alliances (49401)
ALS (86)
Alzheimer's disease (1367)
Antibody-drug conjugate (ADC) (112)
Approvals (16168)
Artificial intelligence (241)
Autoimmune disease (20)
Automation (15)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (18)
Biosimilars (104)
Biotechnology (175)
Bladder cancer (60)
Brain cancer (26)
Breast cancer (262)
Cancer (2083)
Cardiovascular disease (167)
Career advice (1674)
Career pathing (29)
CAR-T (143)
Cell therapy (403)
Cervical cancer (19)
Clinical research (65835)
Collaboration (794)
Compensation (508)
Complete response letters (19)
COVID-19 (2583)
CRISPR (37)
C-suite (223)
Cystic fibrosis (100)
Data (2051)
Decentralized trials (2)
Denatured (17)
Depression (39)
Diabetes (256)
Diagnostics (6348)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (118)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (91)
Earnings (86337)
Editorial (35)
Employer branding (21)
Employer resources (146)
Events (111887)
Executive appointments (693)
FDA (17349)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (717)
Gene editing (100)
Generative AI (19)
Gene therapy (285)
GLP-1 (697)
Government (4403)
Grass and pollen (4)
Guidances (51)
Healthcare (18811)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (109)
Indications (26)
Infectious disease (2723)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (91)
Interviews (311)
IPO (16494)
IRA (40)
Job creations (3628)
Job search strategy (1422)
Kidney cancer (9)
Labor market (36)
Layoffs (460)
Leadership (16)
Legal (7905)
Liver cancer (72)
Lung cancer (302)
Lymphoma (139)
Machine learning (5)
Management (58)
Manufacturing (281)
MASH (62)
Medical device (13344)
Medtech (13349)
Mergers & acquisitions (19434)
Metabolic disorders (655)
Multiple sclerosis (75)
NASH (16)
Neurodegenerative disease (83)
Neuropsychiatric disorders (24)
Neuroscience (1872)
NextGen: Class of 2025 (6512)
Non-profit (4476)
Northern California (2532)
Now hiring (38)
Obesity (353)
Opinion (203)
Ovarian cancer (73)
Pain (80)
Pancreatic cancer (80)
Parkinson's disease (146)
Partnered (21)
Patents (222)
Patient recruitment (99)
Peanut (46)
People (57206)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20505)
Phase II (28988)
Phase III (21606)
Pipeline (1115)
Policy (128)
Postmarket research (2563)
Preclinical (8676)
Press Release (64)
Prostate cancer (98)
Psychedelics (30)
Radiopharmaceuticals (244)
Rare diseases (371)
Real estate (5906)
Recruiting (65)
Regulatory (22198)
Reports (46)
Research institute (2319)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (65)
Series A (124)
Series B (81)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2179)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3572)
State (2)
Stomach cancer (13)
Supply chain (65)
Tariffs (24)
The Weekly (28)
United States (21993)
Vaccines (667)
Venture capitalists (38)
Weight loss (229)
Women's health (34)
Worklife (15)
Date
Today (106)
Last 7 days (500)
Last 30 days (2482)
Last 365 days (32992)
2025 (9195)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54084)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (52)
Alaska (7)
Arizona (229)
Arkansas (13)
Asia (37751)
Australia (6176)
California (5775)
Canada (1939)
China (488)
Colorado (253)
Connecticut (262)
Delaware (134)
Europe (81016)
Florida (860)
Georgia (202)
Idaho (57)
Illinois (513)
India (25)
Indiana (300)
Iowa (9)
Japan (149)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (856)
Massachusetts (4330)
Michigan (215)
Minnesota (378)
Mississippi (2)
Missouri (78)
Montana (27)
Nebraska (25)
Nevada (60)
New Hampshire (62)
New Jersey (1659)
New Mexico (28)
New York (1649)
North Carolina (935)
North Dakota (7)
Northern California (2532)
Ohio (194)
Oklahoma (14)
Oregon (33)
Pennsylvania (1304)
Puerto Rico (11)
Rhode Island (30)
South America (1096)
South Carolina (20)
South Dakota (1)
Southern California (2179)
Tennessee (99)
Texas (860)
Utah (171)
Virginia (135)
Washington D.C. (59)
Washington State (530)
West Virginia (3)
Wisconsin (51)
697,298 Results for "nanoviricides inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NanoViricides, Inc. Has Filed its Quarterly Report
February 20, 2025
·
12 min read
Business
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
NanoViricides, Inc. reports that it has engaged Aagami, Inc. for business development, specifically to seek licensing and partnering opportunities for our assets and platform technology.
May 23, 2024
·
9 min read
Press Releases
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
April 14, 2025
·
10 min read
Press Releases
NanoViricides Engages CRO for Phase II Clinical Trial
January 27, 2025
·
9 min read
Press Releases
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
January 29, 2025
·
9 min read
Press Releases
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
January 14, 2025
·
9 min read
Press Releases
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
February 12, 2025
·
11 min read
Business
NanoViricides Has Filed its Quarterly Report - May 15, 2024
NanoViricides, Inc. reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending March 31, 2024 with the Securities and Exchange Commission on Tuesday, May 14, 2024.
May 15, 2024
·
12 min read
NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
NanoViricides, Inc., a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its current assets and plans towards becoming a successful pharmaceutical company intending to revolutionize the treatment of viral infections.
July 1, 2024
·
9 min read
Drug Development
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon.
April 30, 2024
·
9 min read
1 of 69,730
Next
